Emergent BioSolutions Inc. — Director's Dealing 2017

Nov 30, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-11-28

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-28	Common Stock	M	20000	$22.03	Acquired	1550216	Direct
2017-11-28	Common Stock	S	20000	$41.59	Disposed	1530216	Direct
2017-11-29	Common Stock	M	27983	$22.03	Acquired	1558199	Direct
2017-11-29	Common Stock	S	27983	$42.08	Disposed	1530216	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-28	Employee Stock Options (Right to Buy)	$22.03	M	20000	Disposed	2018-03-14	Common Stock (20000)	Direct
2017-11-29	Employee Stock Options (Right to Buy)	$22.03	M	27983	Disposed	2018-03-14	Common Stock (27983)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4344250	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F2: The selling price of $41.59 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.03 to $41.82, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3: The selling price of $42.08 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.78 to $42.38, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F4: Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F5: Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F6: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014.